Results 11 to 20 of about 195,293 (269)

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia. [PDF]

Genes (Basel), 2023
Lipoprotein apheresis (LA) is a therapeutic option for patients with severe hypercholesterolemia who have persistently elevated LDL-C levels despite attempts at drug therapy. MicroRNAs (miRNAs), important posttranscriptional gene regulators, are involved
Dlouha D, Blaha M, Huckova P, Lanska V, Hubacek JA, Blaha V.   +5 more
europepmc   +4 more sources

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. [PDF]

Lipids Health Dis, 2016
Selective low-density lipoprotein (LDL) apheresis is commonly used to treat patients with familial hypercholesterolemia (FH). Chemerin is an adipokine with putative roles in the regulation of lipid metabolism.
Varga VE, Lőrincz H, Zsíros N, Fülöp P, Seres I, Paragh G, Balla J, Harangi M.   +7 more
europepmc   +4 more sources

A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. [PDF]

Nephron Extra, 2015
Background/Aims: LDL apheresis (LDL-A) is used for drug-resistant nephrotic syndrome (NS) as an alternative therapy to induce remission by improvement of hyperlipidemia. Several clinical studies have suggested the efficacy of LDL-A for refractory NS, but
Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Takemura T, Yuzawa Y, Ogahara S, Sugiyama S, Iino Y, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Imai E, Matsuo S, Saito T.   +23 more
europepmc   +4 more sources

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis

Journal of Lipid Research, 2012
High LDL-cholesterol (LDL-C) characterizes familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH). LDL-apheresis, used in these patients to reduce LDL-C levels, has been shown to also affect HDL levels and composition.
M.P. Adorni, F. Zimetti, M. Puntoni, F. Bigazzi, F. Sbrana, F. Minichilli, F. Bernini, N. Ronda, E. Favari, T. Sampietro   +9 more
doaj   +2 more sources

Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.

Journal of Lipid Research, 1994
To determine the acute and long-term effects of low density lipoprotein (LDL) reduction on cholesterol biosynthesis, we studied changes in the cholesterol precursors mevalonic acid (MVA) and lathosterol in patients with heterozygous familial ...
M Pfohl, R P Naoumova, C Klass, W Knisel, B Jakober, T Risler, G R Thompson   +6 more
doaj   +2 more sources

The Pathological Role of LDL in Membranous Nephropathy and Diabetic Nephropathy and the Protective Efficacy of LDL Apheresis: A Narrative Review [PDF]

Toxins
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease worldwide. One-third of patients with DN develop primary glomerulonephritis, and membranous nephropathy (MN) is the most common concurrent glomerulonephritis.
Goh Kodama, Kensei Taguchi, Yusei Wada, Kaoru Nakano, Ryo Shibata, Kei Fukami   +5 more
doaj   +2 more sources

LDL‐aférese no tratamento de hipercolesterolemia familiar: experiência do Hospital Santo António

Revista Portuguesa de Cardiologia, 2015
Resumo: Introdução: A hipercolesterolemia manifestada pelos níveis elevados de colesterol das lipoproteínas de baixa densidade constitui um fator de risco major para o desenvolvimento e progressão da doença aterosclerótica prematura.A adsorção direta de
Isabel Palma, Ana Rita Caldas, Isabel Mangas Palma, José Alexandre Queirós, Anselmo Madureira, José Carlos Oliveira, Paulo Palma, Carlos Correia, Maria Helena Ramos   +8 more
doaj   +2 more sources

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

Journal of Lipid Research, 2012
In familial hypercholesterolemia (FH), low HDL cholesterol (HDL-C) levels are associated with functional alterations of HDL particles that reduce their capacity to mediate the reverse cholesterol transport (RCT) pathway.
Alexina Orsoni, Elise F. Villard, Eric Bruckert, Paul Robillard, Alain Carrie, Dominique Bonnefont-Rousselot, M. John Chapman, Geesje M. Dallinga-Thie, Wilfried Le Goff, Maryse Guerin   +9 more
doaj   +2 more sources

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia [PDF]

Lipids in Health and Disease, 2011
Background Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.
Minichilli Fabrizio, Bigazzi Federico, Sbrana Francesco, Puntoni Mariarita, Ferdeghini Ezio, Sampietro Tiziana   +5 more
doaj   +2 more sources

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics & Systems Pharmacology
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
doaj   +2 more sources